Compare FTRE & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTRE | CLVT |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2023 | 2020 |
| Metric | FTRE | CLVT |
|---|---|---|
| Price | $18.13 | $2.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 7 |
| Target Price | ★ $14.06 | $3.22 |
| AVG Volume (30 Days) | 1.6M | ★ 5.1M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.75 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,723,400,000.00 | $974,345,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.09 | $2.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.00 | 0.61 |
| 52 Week Low | $8.31 | $1.66 |
| 52 Week High | $21.39 | $4.54 |
| Indicator | FTRE | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 53.44 |
| Support Level | $16.92 | $2.09 |
| Resistance Level | $21.39 | $2.69 |
| Average True Range (ATR) | 0.90 | 0.11 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 51.00 | 83.33 |
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.